News & Updates

Decitabine–vorinostat combo flops in paediatric B-cell acute lymphoblastic leukaemia trial

01 Jun 2020

The combination of decitabine and vorinostat does not appear to be feasible in the treatment of children with B-cell acute lymphoblastic leukaemia (B-ALL), despite encouraging response rates and pharmacodynamics, because of increased incidence of significant infectious toxicities, according to data from the TACL* pilot study.

Decitabine–vorinostat combo flops in paediatric B-cell acute lymphoblastic leukaemia trial

01 Jun 2020

Regular yoga of help for PCOS?

31 May 2020 by

Women with PCOS* who practised mindful yoga thrice weekly had significantly lower free testosterone levels, a main criterion for the diagnosis of PCOS, a small study shows, suggesting yoga as a potential non-pharmacologic complementary treatment option for women with PCOS.

Regular yoga of help for PCOS?

31 May 2020

Mavacamten improves symptoms in nonobstructive hypertrophic cardiomyopathy

31 May 2020

The novel myosin inhibitor mavacamten is well tolerated in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) and leads to a significant decrease in N-terminal pro–B-type natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI), which suggests improvement in myocardial wall stress, a study has shown.

Mavacamten improves symptoms in nonobstructive hypertrophic cardiomyopathy

31 May 2020

Navigating the unknowns in COVID-19 the ACP way

29 May 2020 by

In the face of the COVID-19 pandemic which has taken the world by storm, the lack of approved treatments targeted towards coronavirus has left physicians worldwide grappling with the situation. To help them navigate the black box of COVID-19 management, the ACP* has released a behemoth 28-chapter guide to arm physicians in the virus-infested battle field.

Navigating the unknowns in COVID-19 the ACP way

29 May 2020

Subgroup findings boost elagolix benefit in uterine fibroid-induced menstrual bleeding

29 May 2020 by

The addition of the oral GnRH* antagonist elagolix to hormonal add-back therapy (E2/NETA**) reduces menstrual blood loss (MBL) in women with heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) and comorbid adenomyosis, with the extension phase showing benefits beyond 6 months, according to data presented at ACOG 2020.

Subgroup findings boost elagolix benefit in uterine fibroid-induced menstrual bleeding

29 May 2020

Does a single round of 3HP work for PLWH on ART?

28 May 2020 by

A once-weekly tuberculosis (TB) prevention regimen of isoniazid 900 mg and rifapentine 900 mg given for 3 months (3HP) resulted in higher treatment completion rates vs isoniazid daily for 6 months (6H) in patients with HIV receiving antiretroviral therapy (ART), a study released at CROI 2020 has shown.

Does a single round of 3HP work for PLWH on ART?

28 May 2020

Ingenol mebutate useful for treating actinic keratosis

28 May 2020

Ingenol mebutate is safe and effective in the treatment of patients with actinic keratosis, in addition to exerting a positive impact on quality of life, as shown in a study.

Ingenol mebutate useful for treating actinic keratosis

28 May 2020

Subcutaneous selatogrel inhibits platelet aggregation in AMI patients

28 May 2020

Platelet aggression is inhibited in patients with acute myocardial infarction (AMI) following subcutaneous administration of selatogrel, which induces a profound, rapid, and dose-related antiplatelet response, according to a study.

Subcutaneous selatogrel inhibits platelet aggregation in AMI patients

28 May 2020

Managing acne in primary care

28 May 2020 by

Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.

Managing acne in primary care

28 May 2020

Tenofovir delivers better protection against HCC than entecavir in HBV patients

28 May 2020 by

Persistent hepatitis B virus (HBV) replication contributes to an increased risk of hepatocellular carcinoma (HCC), and suppressing this replication with tenofovir disoproxil fumarate yields greater HCC risk reduction than with entecavir, according to the results of a meta-analysis.

Tenofovir delivers better protection against HCC than entecavir in HBV patients

28 May 2020

News & Updates

Filter by Specialty:

Specialty:

Decitabine–vorinostat combo flops in paediatric B-cell acute lymphoblastic leukaemia trial

Decitabine–vorinostat combo flops in paediatric B-cell acute lymphoblastic leukaemia trial

Regular yoga of help for PCOS?

Regular yoga of help for PCOS?

Mavacamten improves symptoms in nonobstructive hypertrophic cardiomyopathy

Mavacamten improves symptoms in nonobstructive hypertrophic cardiomyopathy

Navigating the unknowns in COVID-19 the ACP way

Navigating the unknowns in COVID-19 the ACP way

Subgroup findings boost elagolix benefit in uterine fibroid-induced menstrual bleeding

Subgroup findings boost elagolix benefit in uterine fibroid-induced menstrual bleeding

Does a single round of 3HP work for PLWH on ART?

Does a single round of 3HP work for PLWH on ART?

Ingenol mebutate useful for treating actinic keratosis

Ingenol mebutate useful for treating actinic keratosis

Subcutaneous selatogrel inhibits platelet aggregation in AMI patients

Subcutaneous selatogrel inhibits platelet aggregation in AMI patients

Managing acne in primary care

Managing acne in primary care

Tenofovir delivers better protection against HCC than entecavir in HBV patients

Tenofovir delivers better protection against HCC than entecavir in HBV patients